CN106420606A - Ceftiofur hydrochloride suspension and preparation method thereof - Google Patents
Ceftiofur hydrochloride suspension and preparation method thereof Download PDFInfo
- Publication number
- CN106420606A CN106420606A CN201610931709.2A CN201610931709A CN106420606A CN 106420606 A CN106420606 A CN 106420606A CN 201610931709 A CN201610931709 A CN 201610931709A CN 106420606 A CN106420606 A CN 106420606A
- Authority
- CN
- China
- Prior art keywords
- suspensoid
- suspension
- oil
- mixture
- magnesium stearate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
- A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a ceftiofur hydrochloride suspension. The raw and auxiliary materials of 2-30 g of ceftiofur hydrochloride, 0.9-1.0 g of surface active agent, 1.0-5.0 g of colloid protective agent, 7.5-12.5 g of suspending agent, 0-0.1% of antioxidant and the balance an oil phase are included per 100 mL of the suspension. Under the condition that specific auxiliary material types and specific using amount and ratios are adopted, the prepared suspension has good physical stability, syringeability and redispersibility, and no quality reduction happens after the suspension is stored for 3 months in the environment of 4-60 DEG C, which shows that the quality of the suspension is stable.
Description
Technical field
The present invention relates to a kind of Ceftiofur Hydrochloride oil suspension and preparation method thereof, belong to field of medicaments.
Background technology
Ceftiofur Hydrochloride, is the third generation cephalosporin of animal specific, be mainly used in treat sensitive organism caused by pig,
Cattle, horse, dog and a Japanese instar chickling infectious disease, are a kind of conventional veterinary drugs.
Insoluble drug is scattered in the heterogeneous liquid preparation formed in oil phase by oil suspension system, and its maximum feature is to make
Drug treating time extend, reduce times for spraying, it is possible to decrease labor intensity and reduce to body stress.However, oil suspension
The preparation of especially oil for injection suspensoid is more difficult, and physical stability to be obtained, syringeability and weight dispersibility preferably produce
Product, determine that suitable supplementary product kind and consumption are very crucial, and, oil suspension is higher to storage environment requirement, improves its storage
Depositing stability is also the factor needing in preparation process to consider.
Record the injection of Ceftiofur Hydrochloride in Ministry of Agriculture's ministry standard, its specification is 2.5%, 5%, 10%,
, using phospholipid, Sorbitan Oleate (span-80) and soybean oil as adjuvant, technique is to take soybean oil to be heated to 80-90 DEG C in right amount for it,
It is cooled to room temperature after adding aluminium stearate 3.0g dissolving, after adding span-80 5.0g and phosphatidase 2 .0g dissolving, add hydrochloric acid cephalo
Thiophene furan stirs, and homogenizing obtains final product.The Ceftiofur Hydrochloride Ceftiofur Hydrochloride oil suspension preparing easily occur flocculation,
Syringeability is poor, after sedimentation caking can not scattered problem, unstable, often because the problem of caking can not use, lead to medicine
Product are wasted in a large number.
Need to provide and a kind of be difficult that flocculation, syringeability be excellent, stay-in-grade Ceftiofur Hydrochloride suspensoid.
Content of the invention
It is an object of the invention to provide a kind of new Ceftiofur Hydrochloride oil suspension and preparation method thereof.
A kind of Ceftiofur Hydrochloride oil suspension, the every 100mL of described suspensoid contains following supplementary material：Ceftiofur Hydrochloride
2～30g, surfactant 0.9g～1.0g, colloid protective agent 1.0g-5.0g, suspending agent 7.5g～12.5g, antioxidant 0%
～0.1%, balance of oil phase.
Preferably, the every 100mL of described suspensoid hydrochloric ceftiofur 2～15g, preferably 10g.
Preferably, described surfactant be tween 80, span-80, in soybean phospholipid any one or multiple,
Preferably ground surfactant is the mixture of tween 80, span-80 and soybean phospholipid, and the weight of three ratio is for 1:1:1.
Preferably, described colloid protective agent is magnesium stearate or the mixture of magnesium stearate and Magnesiumaluminumsilicate；Preferably,
In the mixture of described magnesium stearate and Magnesiumaluminumsilicate, magnesium stearate is 1 with the weight proportion of Magnesiumaluminumsilicate:1；Preferably, institute
When stating the mixture that colloid protective agent is magnesium stearate and Magnesiumaluminumsilicate, the every 100mL 1.0g containing colloid protective agent of described suspensoid
～4.0g, more preferably consumption are 1.0g～3.0g, and most preferred quantities are 1.0g.
Preferably, described antioxidant be vitamin C Petiolus Trachycarpi ester, butylated hydroxyarisol, propylgallate or
Vitamin E.
Preferably, described oil phase is the mixture of soybean oil and benzyl benzoate or isopropyl myristate, the two
Volume ratio is (50～90)：(10～50)；Preferred volume ratio is (70～90):(10～30)；Most preferably volume ratio is 70：30
Soybean oil and the mixture of benzyl benzoate.
Preferably, the every 100mL of described suspensoid contains following supplementary material：Ceftiofur Hydrochloride 10g, soybean phospholipid 0.3g,
Tween 80 0.3g, span-80 0.3g, Magnesiumaluminumsilicate 0.5g, magnesium stearate 0.5g, suspending agent 7.5g～12.5g, benzoic acid
Benzyl ester or isopropyl myristate 30ml, balance of soybean oil.
Preferably, aforementioned suspending agent is being any one in Poloxamer 188, Polyethylene Glycol and sodium carboxymethyl cellulose
Or multiple, the mixture of preferably Poloxamer 188, Polyethylene Glycol and sodium carboxymethyl cellulose, further preferred three's
Weight proportion is (1.0～5.0)：(2.5～5.0)：The weight proportion of (1.0～5.0), most preferably three is 5.0：2.5：1.0.
Present invention also offers the preparation method of aforementioned hydrochloric acid ceftiofur oil suspension agent, comprise the steps：
Oil phase is heated to 60 DEG C～70 DEG C, adds colloid protective agent, surfactant, part suspending agent, add after cooling
Enter remaining suspending agent and Ceftiofur Hydrochloride, mix thoroughly, add oil phase constant volume, homogenizing, obtain final product.
Wherein, every 100ml suspensoid is prepared in accordance with the following steps：Take soybean oil, add benzyl benzoate or myristic acid
Isopropyl ester, is heated to 60 DEG C -70 DEG C, after mix homogeneously, adds the mixture of colloid protective agent Magnesiumaluminumsilicate magnesium stearate, molten
Solution, adds Poloxamer 188 and polyethylene glycol 6000, stirs after fusing, adds surfactant, adds carboxylic after cooling
Sodium carboxymethylcellulose pyce, stirs, and adds Ceftiofur Hydrochloride, is settled to 100ml with soybean oil after stirring, homogenizing, that is,
?.
Under conditions of the specific supplementary product kind of the present invention and consumption proportion, the Ceftiofur Hydrochloride that the present invention prepares
Oil suspension physical stability, syringeability and favorable dispersibility, stablize, and sample passes rate is high, are not in flocculation, cleansing pin
Property poor, sedimentation after lump the problems such as, can overcome existing Ceftiofur Hydrochloride oil suspension easily occur flocculation, syringeability poor, heavy
Caking after fall and the medicine that leads to waste, the waste of human and material resources the problems such as, application prospect is good.
Obviously, the above according to the present invention, according to ordinary technical knowledge and the customary means of this area, without departing from
Under the premise of the present invention above-mentioned basic fundamental thought, modification, replacement or the change of other various ways can also be made.
The specific embodiment of form by the following examples, remakes further specifically to the above of the present invention
Bright.But this scope being interpreted as the above-mentioned theme of the present invention should not be only limitted to Examples below.All based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Specific embodiment
Used in the specific embodiment of the invention, raw material, equipment are known product, are obtained by buying commercially available prod.
The preparation of embodiment 1 Ceftiofur Hydrochloride oil suspension of the present invention
Take soybean oil 30ml, add benzyl benzoate 30ml, after heating (60 DEG C -70 DEG C) mix homogeneously, add colloid to protect
Shield agent Magnesiumaluminumsilicate magnesium stearate (1:1) mixture 1.0g, dissolving, add suspending agent (Poloxamer 188 5.0g, poly- second two
Alcohol 6000 2.5g) stir after fusing, add surfactant soybean phospholipid 0.3g, tween 80 0.3g and span-80
0.3g, adds suspending agent (sodium carboxymethyl cellulose 1.0g) after cooling, stirs, and adds Ceftiofur Hydrochloride 10g, and stirring is all
It is settled to 100ml with soybean oil, homogenizing obtains final product 10% Ceftiofur Hydrochloride oil suspension after even.
The preparation of embodiment 2 Ceftiofur Hydrochloride oil suspension of the present invention
Take soybean oil 30ml, add isopropyl myristate 30ml, after heating (60 DEG C -70 DEG C) mix homogeneously, add glue
Body protective agent Magnesiumaluminumsilicate magnesium stearate (1:1) mixture 1.0g, dissolving, add suspending agent (Poloxamer 188 1.0g, poly-
Ethylene glycol 6000 2.5g) stir after fusing, add surfactant soybean phospholipid 0.3g, tween 80 0.3g and Span-
80 0.3g, add suspending agent (sodium carboxymethyl cellulose 5.0g) after cooling, stir, and add Ceftiofur Hydrochloride 10g, stir
It is settled to 100ml with soybean oil, homogenizing obtains final product 10% Ceftiofur Hydrochloride oil suspension after mixing uniformly.
The preparation of embodiment 3 Ceftiofur Hydrochloride oil suspension of the present invention
Take soybean oil 30ml, add isopropyl myristate 30ml, after heating (60 DEG C -70 DEG C) mix homogeneously, add glue
Body protective agent Magnesiumaluminumsilicate magnesium stearate (1:1) mixture 1.0g, dissolving, add suspending agent (Poloxamer 188 2.5g, poly-
Ethylene glycol 6000 5.0g) stir after fusing, add surfactant soybean phospholipid 0.3g, tween 80 0.3g and Span-
80 0.3g, add suspending agent (sodium carboxymethyl cellulose 5.0g) after cooling, stir, and add Ceftiofur Hydrochloride 10g, stir
It is settled to 100ml with soybean oil, homogenizing obtains final product 10% Ceftiofur Hydrochloride oil suspension after mixing uniformly.
With the mode of experimental example, beneficial effects of the present invention are described below：
The nature examination of experimental example 1 suspensoid of the present invention
1 material
Ceftiofur Hydrochloride, Shandong pharmacy；Benzyl benzoate, Shanghai bright moon daily use chemicals company limited；PEG-4000,
Aladdin reagent company limited；Poloxamer-188, Beijing Feng Li International Trading Company Ltd；Aluminium stearate, magnesium stearate, tell
Temperature -80, the chemical reagent such as span-80, methanol, sodium dihydrogen phosphate, Xi Long Chemical Co., Ltd.；Methanol, match is silent fly generation you (in
State) company limited, homogenizer, Shanghai Heng Chuan plant equipment company limited.
2 methods and result
The investigation method of 2.1 suspensoids
Reference《Chinese veterinary pharmacopoeia》Requirement to suspension, intends checking using the following method that the Ceftiofur Hydrochloride of preparation is suspended
Liquid.
2.1.1 sedimentation volume ratio
Apparatus plug graduated cylinder measures test sample 50ml, close plug, firmly shakes 1min, writes down the beginning height H of suspended matter0, quiet
Put 3 hours, write down the final height H of suspended matter, be calculated as follows：
Sedimentation volume ratio=H/H0
Sedimentation volume ratio is not less than 0.90.
2.1.2 syringeability
Take test sample, with No. 12 needle aspirate, volume aspirated is no less than 2ml in 1 minute after shaking.
2.1.3 dispersibility
With reference to the centrifugation standard of Emulsion, test sample is shaken with after the rotating speed centrifugation 15min of 4000r/min, should easily disperse.
The preparation of 2.2 suspensions
Take solvent appropriate, add surfactant, antioxidant, thickening agent dissolving in the ratio drafted, add after cooling
Ceftiofur Hydrochloride stirs, constant volume, is obtained final product with homogenizer homogenizing.
2.3 solvent
2.3.1 solvent species
Conventional oily suspension solvent is mainly vegetable oil, mineral oil and ester type compound, according to practical situation during test
Employ soybean oil, Oleum Brassicae campestriss, Oleum Arachidis hypogaeae semen, Semen Maydis oil, white oil, ethyl oleate, benzyl benzoate, isopropyl myristate, and
Matching surface activating agent Arlacel-80 (5%, note：5% refers to that Arlacel-80 is 5g with the mass volume ratio of solvent：100mL, after
Percentage ratio implication identical), antioxidant BHA (BHA) (0.02%), thickening agent aluminium stearate
And principal agent Ceftiofur Hydrochloride (10%) prepares different suspensoids, and investigate its sedimentation volume ratio, syringeability, centrifugation (1%)
Deployment conditions afterwards, the results are shown in Table 1.
The effect of table 1 different solvents
As can be seen from Table 1：
Using the solvent of the present invention, will soybean oil and benzyl benzoate or isopropyl myristate, in designated volume
Than under ((50 parts～90 parts)：(10 parts～50 parts)) be applied in combination, can prepare sedimentation volume ratio and syringeability excellent and
The scattered Ceftiofur Hydrochloride oil suspension of energy, wherein, preferred volume ratio is (70～90):The soybean oil of (10～30) and benzene first
The combination of acid benzyl ester, volume ratio are (70～90)：The soybean oil of (10～30) is combined with isopropyl myristate, most preferably body
Long-pending ratio is 70：30 soybean oil is combined with benzyl benzoate.
And be used alone oils or lipid or be applied in combination using soybean oil and other lipids, then cannot take into account simultaneously
Sedimentation volume ratio, syringeability and dispersibility.
2.4 surfactant
Oiliness surface active agent tween -80, span-80 and lecithin as surfactant, above-mentioned test and Selection molten
The Ceftiofur Hydrochloride suspension of agent (soybean oil 70%+ benzyl benzoate 30%) preparation 10%.And investigate its sedimentation volume ratio,
Deployment conditions after syringeability, centrifugation, the results are shown in Table 2.
The effect of table 2 different surfaces activating agent
Can be drawn by the experimental result of table 2, under the conditions of specific solvent of the present invention, using surfactant of the present invention
(tween 80, span-80, soybean phospholipid three alone or both, triple combination's use), total consumption is 0.9～1%,
To prepare qualified Ceftiofur Hydrochloride oil suspension, wherein, preferably 0.3% tween 80+0.3% span-80+0.3%
Soybean phospholipid, the sedimentation volume ratio of its preparation is maximum, and syringeability is excellent and can disperse, and meanwhile, consumption is minimum.
2.5 colloid protective agent
Oil is mainly aluminium stearate, Magnesiumaluminumsilicate etc. with colloid protective agent, and this test intended magnesium stearate is as colloid
Protective agent, and the solvent (soybean oil 70%+ benzyl benzoate 30%) by above-mentioned test and Selection and surfactant (0.3% tells
Temperature -80+0.3% span-80+0.3% soybean phospholipid) preparation 10% Ceftiofur Hydrochloride suspension.And investigate its sedimentation body
Long-pending ratio, syringeability, the deployment conditions after centrifugation, the results are shown in Table 3.
The effect of the different colloid protective agent of table 3
Can be drawn by the experimental result of table 3：
Under the conditions of specific solvent of the present invention, using oil colloid protective agent of the present invention, that is, alone magnesium stearate 1.0～
5.0% or combine that (magnesium stearate is 1 with the weight proportion of Magnesiumaluminumsilicate using magnesium stearate and Magnesiumaluminumsilicate:1) 1.0～
When 4.0%, all can prepare qualified Ceftiofur Hydrochloride oil suspension, wherein, preferable amount is 1.0%～2.0%
Magnesium stearate or magnesium stearate that consumption is 1.0%～3.0% and Magnesiumaluminumsilicate combine (magnesium stearate and Magnesiumaluminumsilicate
Weight proportion be 1:1), most preferred quantities are combining of 1.0% magnesium stearate and Magnesiumaluminumsilicate；
And adopt its excess oil colloid protective agent, then lead to Ceftiofur Hydrochloride suspension color all beyond quality standard
The color gamut of regulation, quality is not good.
2.6 suspending agent
Select medicinal macromolecular substances as suspending agent, including Poloxamer 188, Macrogol 4000, Polyethylene Glycol
6000th, sodium carboxymethyl cellulose, PVP K30, by preliminary experiment, (dispersion in soybean oil for the single substance is real
Test) draw Poloxamer 188, polyethylene glycol 6000, sodium carboxymethyl cellulose, four kinds of material dispersions of PVP K30
Property preferably, and the optimal conditionss obtaining by above-mentioned test prepare 10% Ceftiofur Hydrochloride suspension, investigate its settling volume
Than the deployment conditions after, syringeability, centrifugation, the results are shown in Table 4.
The different suspending agent of table 4 and the effect of consumption
Can be drawn by the experimental result of table 4, under the conditions of specific solvent of the present invention, using this Poloxamer 188, poly- second
Glycol and the combination of sodium carboxymethyl cellulose, total consumption is 7.5～12.5%, and the Ceftiofur Hydrochloride oil that can prepare is mixed
The Ceftiofur Hydrochloride suspension of suspension dispersive property excellent (easily disperseing), its dispersive property is significantly because prepared by other suspending agents
Suspension, wherein, Poloxamer 188 5.0%+ polyethylene glycol 6000 2.5%+ sodium carboxymethyl cellulose 1.0% is optimal.
2.7 antioxidant
Fat-soluble antioxidant is mainly vitamin C Petiolus Trachycarpi ester (0.01%-0.02%), butylated hydroxyarisol
(0.005%-0.02%), propylgallate (0.05%-0.1%), Vitamin E (0.05%-0.075%), by above-mentioned excellent
Choosing solvent, surfactant, colloid protective agent, suspending agent, prepare different Ceftiofur Hydrochloride oil suspensions, and with blank
Comparison, places 12 hours in 60 DEG C of water-baths.
Result shows, adds the suspension of antioxidant all qualified with the suspension quality being not added with antioxidant, and color
Close.
Experimental result illustrates, the present invention is in specific solvent, surfactant, colloid protective agent, suspending agent and consumption
Under the conditions of, in the case of not oxidizer, quality is also preferable.
2.8 preparation technology
Mixing after Poloxamer 188, polyethylene glycol 6000 heating is directly added in oil phase better than the two, this product optimal
Preparation technology is：
Take soybean oil 30ml, add benzyl benzoate 30ml (or isopropyl myristate 30ml, or mixture 30ml), plus
After hot (60 DEG C -70 DEG C) mix homogeneously, add colloid protective agent (Magnesiumaluminumsilicate magnesium stearate mixture 1.0g) dissolving, add
Stir after suspending agent (Poloxamer 188 5.0g, polyethylene glycol 6000 2.5g) fusing, add surfactant Semen sojae atricolor phosphorus
Fat 0.3g, tween 80 0.3g and span-80 0.3g, add suspending agent (sodium carboxymethyl cellulose 1.0g) after cooling, stirring is all
Even, add Ceftiofur Hydrochloride 10g, after stirring, use soybean oil constant volume, homogenizing obtains final product 10% Ceftiofur Hydrochloride oil and is suspended
Liquid.The serviceability test of 2.9 preparation technologies
Prepare 2%, 5%, 10%, 15%, 20%, 30% Ceftiofur Hydrochloride according to above-mentioned optimal preparation technology respectively
Oil suspension, and investigate its sedimentation volume ratio, syringeability, the deployment conditions after centrifugation, the results are shown in Table 5.
The serviceability test of table 5 preparation technology
| Addition and proportioning | Sedimentation volume ratio | Syringeability (ml) | Redispersion after centrifugation |
| 2% | 1.00 | 4.4 | Easily disperse |
| 5% | 1.00 | 4.5 | Easily disperse |
| 10% | 1.00 | 4.2 | Easily disperse |
| 15% | 1.00 | 3.3 | Easily disperse |
| 20% | 1.00 | 2.9 | Easily disperse |
| 30% | 1.00 | 2.7 | Easily disperse |
Can be drawn by upper table, this technique can be used for the preparation of 2%-30% Ceftiofur Hydrochloride oil suspension, but contains
Amount is more excellent less than 15% suspension effect.
2.10 stability test
There is suspension with " 2.8 " 10% Ceftiofur Hydrochloride, be respectively placed in 4 DEG C, 25 DEG C, 40 DEG C and 60 DEG C of environment
Middle placement 3 months, in addition, place in 60 DEG C of environment have detected 10 batch sample for 3 months again.
Quality standard with reference to Ceftiofur Hydrochloride injecta (Ministry of Agriculture novel chiral synthon evaluation center. veterinary medical quality standard is converged
Compile [S]. Chinese agriculture publish color, 2013) detection level, wherein, product 60 DEG C place 3 months qualified, the easy dispersion of content,
Invariant color, illustrates that product can place 2-3 under room temperature (25 DEG C), qualified, the easy dispersion of content, invariant color.
The results are shown in Table 6 and table 7.
The stability test of table 6 different temperatures
| Addition and proportioning | Sedimentation volume ratio | Syringeability (ml) | Redispersion after centrifugation | Content (%) |
| 4℃ | 1.00 | 4.2 | Easily disperse | 99.0 |
| 25℃ | 1.00 | 4.3 | Easily disperse | 99.3 |
| 40℃ | 1.00 | 4.2 | Easily disperse | 99.2 |
| 60℃ | 1.00 | 4.3 | Easily disperse | 99.1 |
The result of table 6 can draw having good stability of this product, places 3 months under various circumstances, plays content, cleansing pin
Property, when bad dispersibility is not different notable for settling volume.
The stability experiment of 3 months is placed in table 60 DEG C of environment of 7 10 batch sample
| Batch | Sedimentation volume ratio | Syringeability (ml) | Redispersion after centrifugation | Content (%) |
| 1 | 1.00 | 3.5 | Easily disperse | 99.1 |
| 2 | 1.00 | 3.6 | Easily disperse | 99.2 |
| 3 | 1.00 | 3.1 | Easily disperse | 98.0 |
| 4 | 1.00 | 3.6 | Easily disperse | 99.4 |
| 5 | 1.00 | 3.5 | Easily disperse | 98.7 |
| 6 | 1.00 | 3.5 | Easily disperse | 98.6 |
| 7 | 1.00 | 3.4 | Easily disperse | 99.1 |
| 8 | 1.00 | 3.2 | Easily disperse | 99.1 |
| 9 | 1.00 | 3.2 | Easily disperse | 98.8 |
| 10 | 1.00 | 3.3 | Easily disperse | 97.6 |
Experimental result illustrates, after Ceftiofur Hydrochloride of the present invention has suspension to place 3 months at 60 DEG C, content is all qualified,
Easily dispersion and invariant color, 10 batch samples find by detection, each sample consistent quality is excellent, all qualified, illustrate that the present invention produces
Product can place 2-3 under the conditions of room temperature (25 DEG C), qualified, the easy dispersion of its content, invariant color, is not in flocculation, syringeability
The phenomenon such as caking after difference, sedimentation, illustrates that the weight of product of the present invention is substantially better than existing commercially available Ceftiofur Hydrochloride oil and is suspended
Agent.
To sum up, the present invention prepares Ceftiofur Hydrochloride oil suspension physical stability, syringeability and dispersibility are good
Good, stablize, and sample passes rate be high, be not in flocculation, syringeability is poor, settle after caking the problems such as, can overcome existing
Flocculating easily occurs in Ceftiofur Hydrochloride oil suspension, syringeability is poor, lump and the problem that leads to product cannot use after sedimentation.
Claims (10)
1. a kind of Ceftiofur Hydrochloride oil suspension, is characterized in that：The every 100mL of described suspensoid contains following supplementary material：Hydrochloric acid
Ceftiofur 2～30g, surfactant 0.9g～1.0g, colloid protective agent 1.0g-5.0g, suspending agent 7.5g～12.5g, anti-
Oxidant 0%～0.1%, balance of oil phase.
2. suspensoid according to claim 1, is characterized in that：The hydrochloric ceftiofur of the every 100mL of described suspensoid 2～
15g, preferably 10g.
3. suspensoid according to claim 1, is characterized in that：Described surfactant is tween 80, span-80, Semen sojae atricolor
In phospholipid any one or multiple, preferably ground surfactant be tween 80, span-80 and soybean phospholipid mixture,
The weight of three is than for 1:1:1.
4. suspensoid according to claim 1, is characterized in that：Described colloid protective agent is magnesium stearate or magnesium stearate
Mixture with Magnesiumaluminumsilicate；Preferably, in the mixture of described magnesium stearate and Magnesiumaluminumsilicate, magnesium stearate and Magnesiumaluminumsilicate
Weight proportion be 1:1；Preferably, when described colloid protective agent is the mixture of magnesium stearate and Magnesiumaluminumsilicate, described suspension
Agent every 100mL 1.0g containing colloid protective agent～4.0g, more preferably consumption are 1.0g～3.0g, and most preferred quantities are
1.0g.
5. suspensoid according to claim 1, is characterized in that：Described antioxidant is vitamin C Petiolus Trachycarpi ester, the tert-butyl group pair
BHA, propylgallate or Vitamin E.
6. suspensoid according to claim 1, is characterized in that：Described oil phase is soybean oil and benzyl benzoate or lima bean
The mixture of cool isopropyl propionate, the volume ratio of the two is (50～90)：(10～50)；Preferred volume ratio is (70～90):(10～
30)；Most preferably volume ratio is 70：30 soybean oil and the mixture of benzyl benzoate.
7. suspensoid according to claim 1, is characterized in that：The every 100mL of described suspensoid contains following supplementary material：Hydrochloric acid
Ceftiofur 10g, soybean phospholipid 0.3g, tween 80 0.3g, span-80 0.3g, Magnesiumaluminumsilicate 0.5g, magnesium stearate 0.5g,
Suspending agent 7.5g～12.5g, benzyl benzoate or isopropyl myristate 30ml, balance of soybean oil.
8. the suspensoid according to claim 1 or 7, is characterized in that：Described suspending agent is being Poloxamer 188, poly- second two
Any one in alcohol and sodium carboxymethyl cellulose or multiple, preferably Poloxamer 188, Polyethylene Glycol and carboxymethyl cellulose
The mixture of plain sodium, the weight proportion of further preferred three is (1.0～5.0)：(2.5～5.0)：(1.0～5.0), optimum
The weight proportion selecting three is 5.0：2.5：1.0.
9. a kind of preparation method of Ceftiofur Hydrochloride oil suspension described in claim 1～8 any one, is characterized in that：Bag
Include following steps：
Oil phase is heated to 60 DEG C～70 DEG C, adds colloid protective agent, surfactant, part suspending agent, add surplus after cooling
Remaining suspending agent and Ceftiofur Hydrochloride, mix thoroughly, add oil phase constant volume, homogenizing, obtain final product.
10. preparation method according to claim 9, is characterized in that：Every 100ml suspensoid is prepared in accordance with the following steps：Take
Soybean oil, adds benzyl benzoate or isopropyl myristate, is heated to 60 DEG C -70 DEG C, after mix homogeneously, adds colloid protection
The mixture of agent Magnesiumaluminumsilicate magnesium stearate, dissolving, add Poloxamer 188 and polyethylene glycol 6000, stir all after fusing
Even, add surfactant, add sodium carboxymethyl cellulose after cooling, stir, add Ceftiofur Hydrochloride, stir
It is settled to 100ml, homogenizing with soybean oil afterwards, obtain final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610931709.2A CN106420606A (en) | 2016-10-31 | 2016-10-31 | Ceftiofur hydrochloride suspension and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610931709.2A CN106420606A (en) | 2016-10-31 | 2016-10-31 | Ceftiofur hydrochloride suspension and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106420606A true CN106420606A (en) | 2017-02-22 |
Family
ID=58177509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610931709.2A Pending CN106420606A (en) | 2016-10-31 | 2016-10-31 | Ceftiofur hydrochloride suspension and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106420606A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403630A (en) * | 2018-05-31 | 2018-08-17 | 佛山市南海东方澳龙制药有限公司 | Suspension and preparation method thereof |
| CN109172519A (en) * | 2018-09-30 | 2019-01-11 | 河南黑马动物药业有限公司 | A kind of Artesunate suspension for animals and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014390A1 (en) * | 2002-08-05 | 2004-02-19 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
| CN101401787A (en) * | 2008-11-19 | 2009-04-08 | 肖希龙 | Ceftiofur long-acting injection and preparation method thereof |
| CN101721366A (en) * | 2010-01-13 | 2010-06-09 | 洛阳惠中兽药有限公司 | Components and preparation method of beta-lactam injection |
| CN103316349A (en) * | 2013-06-21 | 2013-09-25 | 成都乾坤动物药业有限公司 | Oil suspension stabilizer, animal oil suspension with oil suspension stabilizer and preparation method of animal oil suspension |
| CN104758245A (en) * | 2015-03-10 | 2015-07-08 | 河南牧翔动物药业有限公司 | A cefquinome sulfate oily suspension injection and a preparing method thereof |
-
2016
- 2016-10-31 CN CN201610931709.2A patent/CN106420606A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004014390A1 (en) * | 2002-08-05 | 2004-02-19 | Orchid Health Care | Novel pharmaceutical composition of ceftiofur |
| CN101401787A (en) * | 2008-11-19 | 2009-04-08 | 肖希龙 | Ceftiofur long-acting injection and preparation method thereof |
| CN101721366A (en) * | 2010-01-13 | 2010-06-09 | 洛阳惠中兽药有限公司 | Components and preparation method of beta-lactam injection |
| CN103316349A (en) * | 2013-06-21 | 2013-09-25 | 成都乾坤动物药业有限公司 | Oil suspension stabilizer, animal oil suspension with oil suspension stabilizer and preparation method of animal oil suspension |
| CN104758245A (en) * | 2015-03-10 | 2015-07-08 | 河南牧翔动物药业有限公司 | A cefquinome sulfate oily suspension injection and a preparing method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 唐丽华等主编: "《精细化学品复配原理与技术》", 30 June 2008, 中国石化出版社 * |
| 张志成: "盐酸头孢噻呋混悬剂的研制及其稳定性研究", 《中国优秀硕士学位论文全文数据库 农业科技辑》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108403630A (en) * | 2018-05-31 | 2018-08-17 | 佛山市南海东方澳龙制药有限公司 | Suspension and preparation method thereof |
| CN109172519A (en) * | 2018-09-30 | 2019-01-11 | 河南黑马动物药业有限公司 | A kind of Artesunate suspension for animals and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102448441B (en) | Pharmaceutical solution of taxanes comprising ph regulator and preparation method thereof | |
| KR20190114992A (en) | Water Dispersible Formulations | |
| CN106309365A (en) | Cefalexin oil suspension and preparation method thereof | |
| CN106265506A (en) | A kind of amoxicillin colistine sulfate oil suspension and preparation method thereof | |
| CN106420606A (en) | Ceftiofur hydrochloride suspension and preparation method thereof | |
| CN106361707A (en) | Acetylisovaleryl tylosin tartrate granular preparation and preparation method thereof | |
| CN105919941A (en) | Composition containing amoxicillin and potassium clavulanate, and preparation method thereof | |
| CN106344509A (en) | Cefquinome sulfate oil suspension and preparation method thereof | |
| TW202102265A (en) | Novel method for producing lecithin s/o formulation, and formulation therefrom | |
| CN106265505B (en) | A kind of amoxicillin and clavulanate potassium oil suspension and preparation method thereof | |
| JP2019535638A5 (en) | ||
| CN104095815B (en) | The preparation method of the emulsifiable injection of Tulathromycin | |
| US10744109B2 (en) | Sustained release suspension containing dezocine analogue ester and preparation method therefor | |
| CN102458382B (en) | Oil-in-water emulsion of mometasone and propylene glycol | |
| CN106109412A (en) | Flurbiprofen axetil lipid microsphere injection and preparation method thereof | |
| CN106420609A (en) | Amoxicillin oil suspension and preparation method thereof | |
| CN106377499A (en) | Ampicillin oil suspension and preparation method thereof | |
| CN107693504A (en) | A kind of Choline Chloride microcapsule formulation and preparation method thereof | |
| CN105853352B (en) | A kind of suspension composition and preparation method thereof containing pranoprofen | |
| CN106420608A (en) | Oil suspension with procaine benzylpenicillin and method for preparing oil suspension | |
| CN106309360B (en) | A kind of preparation method of long-acting ceftiofur hydrochloride injection | |
| CN106727567A (en) | A kind of Amoxicillin Enrofloxacin oil suspension and preparation method thereof | |
| CN106137963A (en) | Antiarrhythmic drug fat emulsion injection and preparation method thereof | |
| CN1615899B (en) | Puerarin oral preparation | |
| CN106309460A (en) | Amoxicillin gentamicin sulphate oil suspension and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170222 |